医学
临床终点
不利影响
胃肠病学
内科学
脓肿
克罗恩病
粪便细菌疗法
炎症性肠病
外科
疾病
临床试验
抗生素
艰难梭菌
微生物学
生物
作者
Zhiqing He,Pan Li,Jianguo Zhu,Bota Cui,Lijuan Xu,Jie Xiang,Ting Zhang,Chuyan Long,Guangming Huang,Guozhong Ji,Yongzhan Nie,Kaichun Wu,Daiming Fan,Faming Zhang
标识
DOI:10.1038/s41598-017-04984-z
摘要
The ancient Chinese medical literature, as well as our prior clinical experience, suggests that fecal microbiota transplantation (FMT) could treat the inflammatory mass. We aimed to evaluate the efficacy and safety of multiple fresh FMTs for Crohn's disease (CD) complicated with intraabdominal inflammatory mass. The "one-hour FMT protocol" was followed in all patients. Twenty-five patients were diagnosed with CD and related inflammatory mass by CT or MRI. All patients received the initial FMT followed by repeated FMTs every 3 months. The primary endpoint was clinical response (improvement and remission) and sustained clinical remission at 12 months. Secondary endpoints were improvement in size of phegmon/abscess based upon cross-sectional imaging and safety of FMT. 68.0% (17/25) and 52.0% (13/25) of patients achieved clinical response and clinical remission at 3 months post the initial FMT, respectively. The proportion of patients at 6 months, 12 months and 18 months achieving sustained clinical remission with sequential FMTs was 48.0% (12/25), 32.0% (8/25) and 22.7% (5/22), respectively. 9.5% (2/21) of patients achieved radiological healing and 71.4% (15/21) achieved radiological improvement. No severe adverse events related to FMT were observed. This pragmatic study suggested that sequential fresh FMTs might be a promising, safe and effective therapy to induce and maintain clinical remission in CD with intraabdominal inflammatory mass.
科研通智能强力驱动
Strongly Powered by AbleSci AI